Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call

Bacterin International Holdings, Inc. Schedules Fourth

Quarter 2011 Financial Earnings Conference Call

BELGRADE, Mont. Feb. 24, 2012 - Bacterin International

Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings

for medical applications, will release its financial results for the three and 12 months ended December 31, 2011 after the close

of regular market trading on Thursday, March 22, 2012. A conference call will follow at 4:30 p.m. Eastern Time (1:30 p.m. Pacific

Conference Call Details:

Date: Thursday, March 22, 2012

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Dial-In Number: 1-877-941-1427

International: 1-480-629-9664

Conference ID#: 4519974

The conference call will be broadcast simultaneously and available

for replay here and at the investor section of the company's Web site at http://www.bacterin.com/index.htm.

Please call the conference telephone number 5-10 minutes

prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference

call, please contact Hayden IR at 1-646-755-7412.

A replay of the call will be available after 7:30 p.m. Eastern

time on the same day and until April 22, 2012.

International replay number: 1-858-384-5517

Replay pin number: 4519974

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE)

develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods

optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair

and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of

back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral

repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs,

and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include

antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please

visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be

deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to

significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon

or refer to future events or conditions, or that include words such as "continue," "efforts," "expects,"

"anticipates," "intends," "plans," "believes," "estimates," "projects,"

"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"

"optimistic," "confident," "likely," "probable" or similar expressions or the negative

thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by

their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors,

including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence

use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated

contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services

and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of

the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability

to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain

management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions

and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed

in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to

release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to

reflect the occurrence of unanticipated events, except as required by law.

James Carbonara, Regional Vice President, 646-755-7412

Brett Maas, 646-536-7331